Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants
Starting soon · Phase 1
Conditions studied: Healthy Volunteers
In brief
This study aims to evaluate the effects of food or ethnicity on the pharmacokinetics and safety/tolerability of JPI-547 after a single oral administration in healthy male Korean, Caucasian, and Chinese participants.
Key facts
- Study ID
- NCT07570186
- Run by
- Onconic Therapeutics Inc.
- People needed
- 36
- Starts
- 2026-05-01
- Expected to finish
- 2026-07-01
- Last updated by the study team
- 2026-05-06
Who can join
Age: 19 and older, up to 50. Sex: male. Healthy volunteers: accepted.
You may qualify if…
- Healthy Korean, Caucasian, or Chinese male participants aged 19 to 50 years at screening
- Body weight between 50.0 and 90.0 kg and BMI between 18.5 and 29.9 kg/m²
- Able to understand the study and provide written informed consent
- Considered suitable for study participation by the investigator based on medical history, physical examination, and clinical laboratory tests
You may not qualify if…
- Clinically significant medical or surgical history
- Gastrointestinal disease or surgery affecting drug absorption
- Hypersensitivity to PARP inhibitors or other significant drug allergy
- Drug abuse history or positive drug screening
- Clinically significant abnormal vital signs or laboratory results
- Positive viral or serologic screening tests
- Recent use of prohibited medications
- Recent participation in another clinical trial
- Recent blood donation or transfusion
- Inability to abstain from smoking, alcohol, caffeine, or grapefruit
- Failure to comply with contraception or sperm donation requirements
- Any condition making the participant unsuitable in the investigator's judgment
Where it is running
- Seoul National University Hospital — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.